Chonnam National University Hospital and Nexel Sign MOU for Research Collaboration in the Bio Sector

[Asia Economy Honam Reporting Headquarters Reporter Yoon Jamin] Jeonnam National University Hospital (Director Lee Sam-yong) announced on the 19th that it signed a business agreement for research cooperation in the bio field with the cutting-edge bio company Nexel Co., Ltd. (CEO Han Chung-sung) on the 18th.

About 20 officials from both organizations attended the signing ceremony, including Director Lee Sam-yong, Director Kim Byung-chae of the Biomedical Research Institute, Professor Ahn Young-geun of the Department of Cardiology, and CEO Han Chung-sung.

According to the agreement, both organizations will promote ▲ mutual cooperation on joint research results using induced pluripotent stem cells ▲ consultation on the utilization of results derived from cooperation between the two organizations ▲ sharing of human-derived materials and related information and mutual cooperation on research utilizing them.

Nexel is the only domestic company holding the patent license for induced pluripotent stem cells from Kyoto University in Japan, and based on specialized stem cell differentiation technology, it has succeeded in developing various somatic cell products targeting the global toxicology testing cell market.

It is an advanced bio company focusing on new drug development and stem cell research and development, developing somatic cell products derived from stem cells for toxicity testing for new drug development of treatments for liver cirrhosis, myocardial infarction, and pulmonary fibrosis.

Director Lee Sam-yong said, “This agreement has become an opportunity to accelerate new drug development for genetic diseases and stem cell development,” and added, “We will spare no support to achieve excellent research outcomes that lead future medicine through cooperation between the two organizations.”

This content was produced with the assistance of AI translation services.